Cue Biopharma earnings missed by $3.39, revenue fell short of estimates

Cue Biopharma (CUE) reported Q3 EPS of -$4.74, missing estimates by $3.39, with revenue of $10K, below the $1.55M consensus. The stock is down 42.71% over 3 months and 18.12% over 12 months. InvestingPro rates its financial health as weak.

Original reporting
Published Nov 16, 2026, 10:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CUE
Bearish
high confidence
Mentioned
$CUE
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CUEBearishMed
01

Why it matters

The magnitude of the EPS miss and the reported revenue shortfall are likely to dominate trader focus on solvency risk and the credibility of the path to meaningful revenue.

02

Market read

Traders can reassess valuation and near-term risk after the company’s quarterly print missed both EPS and revenue expectations.

03

What to watch

The article does not include guidance, cash balance, burn rate, or management commentary, which are often decisive for biotech post-earnings direction.

Relevance 9/10Novelty 8/10Timing: after-hours/earnings release window (published 2026-11-16 22:47 UTC)

Background

The piece summarizes Cue Biopharma’s Q3 results versus analyst consensus and notes weak financial health.

Company-level read

Ticker impact

$CUEBearishHigh confidence
Context

Cue Biopharma reported Q3 EPS of -4.740, missing the -1.350 estimate, and revenue of $10K versus $1.55M consensus.

Expected impact

Likely downward pressure as the market reprices the company’s revenue trajectory and cash-burn expectations after the miss.

Evidence & confidence

The article provides the company’s own quarterly EPS and revenue figures versus consensus, which are direct drivers of post-earnings sentiment and valuation for a micro/small-cap biotech.

Market effects

Reinforces risk-off sentiment toward pre-commercial or revenue-light biotech names when quarterly revenue prints miss sharply.

Limited spillover expected beyond US small-cap biotech sentiment.

Low, company-specific earnings miss with no cross-market catalyst described.

Counterpoint

If the revenue shortfall reflects timing (e.g., delayed recognition) rather than demand collapse, the stock could stabilize on any qualitative commentary not captured here.

Key entities

  • Cue Biopharma

    NASDAQ-listed biotech reporting Q3 EPS and revenue versus consensus.

Related articles

$CUEMed

Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights • CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and fo

$CUEMedAI 8/10

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma (CUE) reported positive Phase 2 results for CUE-221 in treating chronic hives, with 54% of patients achieving complete hive resolution vs. 11% on placebo. The drug showed sustained relief 12 weeks post-treatment, with 60% of patients in the highest-dose group remaining hive-free. No serious adverse events were reported. The company plans a Phase 2b/3 study and has $67.4M in cash after recent financing.

$CUEMedAI 9/10

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling stu